Published in Women's Health Weekly, January 12th, 2006
"Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. This study investigates the role of BCRP in resistance of ovarian cancer to TPT treatment," wrote P. Jia and colleagues, Huazhong University of Science & Technology.
"We have developed TPT-resistant human ovarian cancer cell line. Intracellular concentration of fluorescent dye rhodamine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.